This NIDDK grant is for the purpose of renewing the Inflammatory Bowel Disease Genetics Consortium (IBDGC). Its mission is to advance understanding of IBD’s genetic architecture, especially in under-represented populations. The grant aims to elucidate the biological mechanisms by which genetic variants influence IBD pathophysiology, phenotypes, and outcomes. Ultimately, this research seeks to improve disease course prediction and treatment strategies. Genetic Research Centers (GRCs) funded by this grant will serve as crucial sites for enrolling IBD patients, relatives, and healthy controls. They will conduct laboratory-based studies on biological samples and perform mechanistic studies on identified variants, genes, proteins, and pathways. GRC Program Directors will be integral voting members of the IBDGC Steering Committee, guiding operational decisions.
Opportunity ID: 335545
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-DK-21-022 |
| Funding Opportunity Title: | NIDDK Inflammatory Bowel Disease Genetics Consortium (IBDGC) Genetic Research Centers (GRCs) (U01 Clinical Trial Optional) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Food and Nutrition Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.847 — Diabetes, Digestive, and Kidney Diseases Extramural Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Sep 02, 2021 |
| Last Updated Date: | Sep 02, 2021 |
| Original Closing Date for Applications: | Dec 21, 2021 |
| Current Closing Date for Applications: | Dec 21, 2021 |
| Archive Date: | Jan 26, 2022 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | $375,000 |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | For profit organizations other than small businesses State governments City or township governments Public and State controlled institutions of higher education Others (see text field entitled “Additional Information on Eligibility” for clarification) County governments Special district governments Independent school districts Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Small businesses Public housing authorities/Indian housing authorities Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education Native American tribal organizations (other than Federally recognized tribal governments) Native American tribal governments (Federally recognized) |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | The NIDDK Inflammatory Bowel Disease Genetics Consortium (IBDGC) was established in July 2002 for the purpose of identifying genetic variation predisposing to Inflammatory Bowel Disease (IBD). Since its establishment and in collaboration with the International IBD Genetics Consortium, the NIDDK IBDGC has identified over 250 IBD susceptibility loci. However, for the great majority of these loci, the specific causal variants and effector genes have not yet been identified, and the biological mechanisms through which these variants influence IBD pathophysiology remain to be elucidated. The purpose of this FOA is to renew the IBDGC with a continued mission to characterize the genetic architecture of IBD and its sub-phenotypes, particularly in populations currently under-represented in IBD genomic studies, and to elucidate the biological mechanisms by which genetic variants influence IBD pathophysiology, phenotypes and outcomes, with the long-term goal of improving disease course prediction and treatment. The Genetic Research Centers (GRCs) of the IBDGC will serve as sites for enrollment of IBD patients, relatives and healthy controls, for laboratory-based studies on biological samples taken from these subjects, and for mechanistic studies of the variants identified and of the genes, proteins and pathways they impact. The Program Directors / Principal Investigators of the GRCs will serve as voting members of the Steering Committee of the IBDGC, which will be responsible for all operational decisions, which will be binding upon all members of the IBDGC. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-21-022.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
OERWebmaster03@od.nih.gov Email:OERWebmaster03@od.nih.gov |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
There are no related documents on this grant.
Packages
| Agency Contact Information: | NIH OER Webmaster OERWebmaster03@od.nih.gov Email: OERWebmaster03@od.nih.gov |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-G | Use for due dates on or after January 25, 2022 | PKG00270451 | Nov 21, 2021 | Dec 21, 2021 | View | |
| FORMS-F | Use for due dates on or before January 24, 2022 | PKG00268790 | Nov 21, 2021 | Jan 24, 2022 | View |
Package 1
Mandatory forms
335545 RR_SF424_5_0-5.0.pdf
335545 PHS398_CoverPageSupplement_5_0-5.0.pdf
335545 RR_OtherProjectInfo_1_4-1.4.pdf
335545 PerformanceSite_4_0-4.0.pdf
335545 RR_KeyPersonExpanded_4_0-4.0.pdf
335545 PHS398_ResearchPlan_4_0-4.0.pdf
335545 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
335545 RR_Budget_3_0-3.0.pdf
335545 RR_SubawardBudget30_3_0-3.0.pdf
335545 PHS398_ModularBudget_1_2-1.2.pdf
335545 PHS_AssignmentRequestForm_3_0-3.0.pdf
Package 2
Mandatory forms
335545 RR_SF424_2_0-2.0.pdf
335545 PHS398_CoverPageSupplement_5_0-5.0.pdf
335545 RR_OtherProjectInfo_1_4-1.4.pdf
335545 PerformanceSite_2_0-2.0.pdf
335545 RR_KeyPersonExpanded_2_0-2.0.pdf
335545 PHS398_ResearchPlan_4_0-4.0.pdf
335545 PHSHumanSubjectsAndClinicalTrialsInfo_2_0-2.0.pdf
Optional forms
335545 RR_Budget_1_4-1.4.pdf
335545 RR_SubawardBudget30_1_4-1.4.pdf
335545 PHS398_ModularBudget_1_2-1.2.pdf
335545 PHS_AssignmentRequestForm_3_0-3.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
